The efficacy of GLP-1 receptor agonists (GLP-1RA) was recently analysed in a meta-analysis by Wong et al., who reported a reduction in hepatic fat content in patients with T2D and NAFLD treated with GLP-1RA, which also ameliorated hepatic function (ALT, AST, and GGT normalization) and markers of inflammation, also being effective in reducing BMI and visceral adipose tissue [116], results similar to those obtained by Mantovani et al. in their meta-analysis. The gene discussed is GPT; the disease is type 2 diabetes mellitus.